ENTITY
SK Biopharmaceuticals

SK Biopharmaceuticals (326030 KS)

121
Analysis
Health CareSouth Korea
SK Biopharmaceuticals Co., Ltd. researches and develops new drugs. The Company develops and markets brain disorders treatment drugs, central nervous system disorders treatment drugs, and other products. SK Biopharmaceuticals markets its products worldwide.
more
Refresh
02 Jul 2020 00:03

Do What the Locals Do - BUY Celltrion/Samsung Bio/SK Holdings on SK Biopharma Listing

Local institutions in Korea will have a significant underperformance on SK Biopharm listing and will clamor to buy and makeup for their...

Logo
352 Views
Share
01 Jul 2020 18:07

SK Biopharmaceuticals: Immediate Post IPO Float Is 13% (Not 5%)

What's the post-IPO float of SK Biopharm?It is much higher than what it first appeared after the book-building.Below is the final allocation....

Logo
430 Views
Share
01 Jul 2020 06:11

Korea Stock Market Monthly Recap #49 (June 2020)

Review of Top 10 Issues Related to Korean stock market, economy, & politics in June 2020: SK Biopharm IPO SK Holdings downgrade Capital gains...

Logo
365 Views
Share
bearishSK Inc
25 Jun 2020 07:40

KB Bank Sells 2.5% Stake in SK Holdings in a Block Deal

Yesterday, KB Kookmin Bank sold about 2.5% of its stake in SK Holdings (034730 KS) for about 500 billion won in a "club deal basis" to foreign...

Logo
329 Views
Share
24 Jun 2020 08:54

KOSPI200 Index Rebalance Preview - Positioning Begins for December

The Korea Exchange (KRX) will announce the results of the December 2020 review of the Korea Stock Exchange Kospi 200 Index (KOSPI2 INDEX) in...

Logo
778 Views
Share
x